Association of genetic polymorphisms of brain natriuretic peptide with cardiovascular diseases
https://doi.org/10.15829/1560-4071-2024-5906
EDN: UGAWRK
Abstract
Currently, natriuretic peptides (including brain natriuretic peptide (BNP)) are widely used in clinical practice as biomarkers for various cardiovascular diseases. Study of the structure and function of NPPA-NPPB locus can help to better identify patients at risk of future cardiovascular diseases, in particular heart failure.
About the Authors
A. Ya. Panarina
Institute of Chemical Biology and Fundamental Medicine
Russian Federation
Competing Interests:
Russian Federation
Novosibirsk
Competing Interests:
None
G. I. Lifshits
Institute of Chemical Biology and Fundamental Medicine
Russian Federation
Competing Interests:
Russian Federation
Novosibirsk
Competing Interests:
None
References
1. Nikolaev KYu, Shilova AV, Kovaleva AYa, Lifshits GI. Role of brain natriuretic peptide in the pathogenesis of resistant hypertension. Russian Journal of Cardiology. 2023;28(1):5188. (In Russ.) doi:10.15829/1560-4071-2023-5188.
2. Litvinukova M, Talavera-Lopez C, Maatz H, et al. Cells of the adult human heart. Nature. 2020;588:466-72. doi:10.1038/s41586-020-2797-4.
3. Rubattu S, Stanzione R, Cotugno M, et al. Epigenetic control of natriuretic peptides: implications for health and disease. Cell. Mol. Life Sci. 2020;77:5121-30. doi:10.1007/s00018-020-03573-0.
4. Slepukhina AA, Zelenskaya EM, Lifshits GI. Genetic risk factors for vascular aging: molecular mechanisms, polymorphism of candidate genes and gene networks. Russian Journal of Cardiology. 2019;(10):78-85. (In Russ.) doi:10.15829/1560-4071-2019-10-78-85.
5. Kuhn M.Molecular Physiology of Membrane Guanylyl Cyclase Receptors. Physiol Rev. 2016;96(2):751-804. doi:10.1152/physrev.00022.2015.
6. Qiao Z, Zheng KI, Zhu P, et al. Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. Nutr Metab Cardiovasc Dis. 2020;30(10):1820-25. doi: 10.1016/j.numecd.2020.05.017.
7. Okamoto C, Tsukamoto O, Hasegawa T, et al. Lower B-type natriuretic peptide levels predict left ventricular concentric remodelling and insulin resistance. ESC Heart Fail. 2022;9(1):636-47. doi:10.1002/ehf2.13700.
8. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012.
9. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.
10. Kayani M, Fatima N, Yarra PC, et al. Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review. Cureus. 2024;16(2):e53445. doi:10.7759/cureus.53445.
11. Man JCK, van Duijvenboden K, Krijger PHL, et al. Genetic Dissection of a Super Enhancer Controlling the Nppa-Nppb Cluster in the Heart. Circ Res. 2021;128(1):115-29. doi:10.1161/CIRCRESAHA.120.317045.
12. Kovаlevа АYа, Kokh NV, Voroninа EN, et al. Identification of ethnogenetic differences in genetic markers in the clinical course and damage to target organs in arterial hypertension in Russians and Buryats. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2020;24(4):103-13. (In Russ.) doi:10.21688/1681-3472-2020-4-103-113.
13. Gidlöf O. Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure. Front Physiol. 2021;12:650124. doi:10.3389/fphys.2021.650124.
14. Salo PP, Havulinna AS, Tukiainen T, et al. Genome-Wide Association Study Implicates Atrial Natriuretic Peptide Rather Than B-Type Natriuretic Peptide in the Regulation of Blood Pressure in the General Population. Circ Cardiovasc Genet. 2017;10(6):e001713. doi:10.1161/CIRCGENETICS.117.001713.
15. Johansson Å, Eriksson N, Lindholm D, et al. PLATO Investigators. Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Hum Mol Genet. 2016;25(7):1447-56. doi:10.1093/hmg/ddw012.
16. Abuzaanona A, Lanfear D.Pharmacogenomics of the Natriuretic Peptide System in Heart Failure. Curr Heart Fail Rep. 2017;14(6):536-42. doi:10.1007/s11897-017-0365-5.
17. Man J, Barnett P, Christoffels VM. Structure and function of the Nppa-Nppb cluster locus during heart development and disease. Cell Mol Life Sci. 2018;75(8):1435-44. doi:10.1007/s00018-017-2737-0.
18. Xhaard C, Rouget R, Vodovar N, et al. Impact of natriuretic peptide polymorphisms on diastolic and metabolic function in a populational cohort: insights from the STANISLAS cohort. ESC Heart Fail. 2022;9(1):729-39. doi:10.1002/ehf2.13674.
19. Yang Y, Zmuda JM, Wojczynski MK, et al. Genetic association analysis of the cardiovascular biomarker: N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP). PLoS One. 2021;16(3):e0248726. doi:10.1371/journal.pone.0248726.
20. Seidelmann SB, Vardeny O, Claggett B, et al. An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. J Am Heart Assoc. 2017;6(4):e005257. doi:10.1161/JAHA.116.005257.
21. Cannone V, Ledwidge M, Watson C, et al. STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure. JACC Basic Transl Sci. 2021;6(6):497-504. doi:10.1016/j.jacbts.2021.05.001.
22. Cataliotti A, Tonne JM, Bellavia D, et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011;123(12):1297-305. doi:10.1161/CIRCULATIONAHA.110.981720.
Supplementary files
- The use of natriuretic peptide markers (BNP and/or NT-proBNP) in combination with other diagnostic methods — electrocardiography, chest radiography and echocardiography, remains the gold standard for the diagnosis of heart failure (HF).
- Genetic testing of natriuretic peptide markers is an important step towards personalized care for HF.
- Future studies are needed to study the importance of the contribution of BNP genetic testing and BNP-based therapy in the treatment and prevention of HF.
Review
For citations:
Panarina A.Ya., Lifshits G.I. Association of genetic polymorphisms of brain natriuretic peptide with cardiovascular diseases. Russian Journal of Cardiology. 2024;29(10):5906. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5906. EDN: UGAWRK
Views:
218
Email this article 